Combining paclitaxel and lapatinib as second-line treatment for patients with metastatic transitional cell carcinoma: a case series.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Anticancer Research

• Publication date

  2012-09-01

• Fields of study

  Medicine

• Identifiers
  PMID 22993342
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium

  2010cited by this paper
• Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.

  2010cited by this paper
• A single‐arm, multicenter, open‐label phase 2 study of lapatinib as the second‐line treatment of patients with locally advanced or metastatic transitional cell carcinoma

  2009cited by this paper
• A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102.

  2009cited by this paper
• Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients

  2009cited by this paper
• Lapatinib, a dual inhibitor of ErbB-1/-2 receptors, enhances effects of combination chemotherapy in bladder cancer cells.

  2009cited by this paper
• Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.

  2009cited by this paper
• Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study.

  2009cited by this paper
• Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer.

  2008cited by this paper
• Pooled analysis of diarrhea events in patients with cancer treated with lapatinib

  2008cited by this paper
• Epidermal growth factor receptor status and the response of bladder carcinoma cells to erlotinib.

  2007cited by this paper
• Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.

  2006cited by this paper
• Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.

  2005cited by this paper
• Evaluation of the Therapeutic Potential of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib in Preclinical Models of Bladder Cancer

  2004cited by this paper
• Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder.

  2001cited by this paper
• Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice.

  1999cited by this paper

• HER2 and urothelial carcinoma: current understanding and future directions

  2025influential citation
• A narrative review of advances in the management of urothelial cancer: Diagnostics and treatments

  2024cites this paper
• Repurposing of Loperamide as a New Drug With Anticancer Activity for Human Osteosarcoma

  2024cites this paper
• Progress in systemic therapy for advanced-stage urothelial carcinoma

  2023cites this paper
• The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives.

  2022cites this paper
• Clinical Trial Outcomes: What Matters to Patients.

  2019cites this paper
• Tumor Mutational Burden

  2018cites this paper
• Prospects for precision therapy of bladder urothelial carcinoma

  2017cites this paper
• Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer.

  2017cites this paper
• Chapter 11 – Lapatinib

  2017cites this paper
• Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU)

  2016cites this paper
• Novel Molecular Targets for the Therapy of Urothelial Cancer.

  2015cites this paper
• Carboplatin, methotrexate, vinblastine, and epirubicin (M-VECa) as salvage treatment in patients with advanced bladder cancer: a phase II study

  2015cites this paper
• Targeting Hsp90 in urothelial carcinoma

  2015cites this paper
• HER2/neu: an increasingly important therapeutic target. Part 3: clinical applications and investigations

  2014cites this paper
• Clinical Trial Outcomes part of HER 2 / neu : an increasingly important therapeutic target . Part 3 : clinical applications and investigations

  2014cites this paper
• Second-line systemic therapy for metastatic urothelial carcinoma of the bladder.

  2013cites this paper